Genesis Therapeutics
Davide Sabbadin currently serves as a Research Fellow in Computational Drug Design and Development at Genesis Therapeutics since August 2025 and holds the position of Invited Professor at the University of Applied Sciences and Arts Northwestern Switzerland FHNW since January 2020. Previous roles include Director and Associate Director of Computational Chemistry at VantAI from May 2022 to August 2025, and Drug Discovery and Applications Lead Scientist at Qubit Pharmaceuticals from February 2021 to May 2022. As the Computational Chemistry Lead Scientist at Autifony Therapeutics from March 2019 to February 2021, Davide led the computational chemistry efforts while collaborating on structural biology and compound optimization. Expertise spans various positions, including Drug Discovery Specialist at Universitat Pompeu Fabra and leading computational chemistry teams at Syngenta, alongside a robust academic background including a Ph.D. from the University of Padova. Notable achievements include advancements in lead generation techniques and the application of computational methods in drug discovery.
This person is not in any teams
This person is not in any offices
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.